Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy?

Academic Radiology

Volumn 9, Issue 7, 2002, Pages 773-783

  Samson, David J ^a   Flamm, Carole Redding ^a   Pisano, Etta D ^b   Aronson, Naomi ^a  

^a Blue Cross and Blue Shield Association   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast neoplasms, diagnosis; Breast neoplasms, radionuclide studies; Breast, biopsy; Breast, radionuclide studies

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; BREAST BIOPSY; BREAST DISEASE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDLINE; META ANALYSIS; PATIENT CARE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 0036317912     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(03)80347-1     Document Type: Article

References (30)

1. Breast cancer screening for women ages 40-49
2. The prevalence of carcinoma in palpable vs. impalpable, mammographically detected lesions
3. Positive predictive value of the Breast Imaging Reporting and Data System
4. The Breast Imaging Reporting and Data System: Positive predictive value of mammographic features and final assessment categories
5. BI-RADS categorization as a predictor of malignancy
6. New directions in breast biopsy: Review of current minimally invasive methods and presentation of a new coaxial technique
7. Positron emission tomography: Applications in oncology
8. Principles of positron emission tomography
9. Guideline for meta-analysis evaluating diagnostic tests
10. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis
11. Fluorine-18 2-deoxy-2fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard imaging procedures
12. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations
13. Positron emission mammographic instrument: Initial results
14. Positron emission tomography in breast cancer: A clinicopathological correlation of results
15. Diagnostic value of positron emission tomography for detecting breast cancer
16. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET
17. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours
18. Evaluation of preoperative chemotherapy using PET with fluorine-18- fluorodeoxyglucose in breast cancer
19. Qualitative [18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
20. Positron emission tomography and breast masses: Comparison with clinical, mammographic, and pathological findings
21. Cancer detection with wholebody PET using 2-[18F]fluoro-2-deoxy-D-glucose
22. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
23. Breast imaging with fluorine-18-FDG PET: Quantitative image analysis
24. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
25. Effect of patients' being prone during FDG PET for the diagnosis of breast cancer
26. Evaluation of breast masses and axillary lymph nodes with [18F] 2-deoxy-2-fluoro-D-glucose PET
27. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease